This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Delta-like 1 (DLL1)	<p>Mouse studies suggest increasing DLL1 activity could improve the efficacy of cancer immunotherapies. In immune competent mice, a soluble DLL1 variant inhibited tumor growth compared with a control protein. Next steps include developing an optimized, multivalent DLL1 variant for undisclosed therapeutic applications.</p> <p><i>SciBX</i> 4(33); doi:10.1038/scibx.2011.927 Published online Aug. 25, 2011</p>	Patent application filed; available for licensing	<p>Huang, Y. <i>et al. Cancer Res.</i>; published online Aug. 8, 2011; doi:10.1158/0008-5472.CAN-10-4366 Contact: David P. Carbone, Vanderbilt University, Nashville, Tenn. e-mail: d.carbone@vanderbilt.edu</p>